Aspiriant LLC’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$451K Buy
5,770
+211
+4% +$17K 0.01% 261
2026
Q1
$482K Buy
5,559
+2,000
+56% +$192K 0.01% 223
2025
Q4
$342K Buy
3,559
+324
+10% +$31.5K 0.01% 259
2025
Q3
$308K Sell
3,235
-38
-1% -$3.49K 0.01% 247
2025
Q2
$285K Sell
3,273
-133
-4% -$11.3K 0.01% 263
2025
Q1
$306K Buy
+3,406
New +$305K 0.01% 233
2024
Q2
Sell
-2,592
Closed -$226K 314
2024
Q1
$226K Sell
2,592
-380
-13% -$32.4K 0.01% 294
2023
Q4
$245K Sell
2,972
-559
-16% -$42.6K 0.01% 268
2023
Q3
$277K Buy
3,531
+786
+29% +$65.8K 0.01% 237
2023
Q2
$242K Buy
2,745
+138
+5% +$11.9K 0.01% 253
2023
Q1
$210K Buy
+2,607
New +$212K 0.01% 263
2022
Q4
Sell
-3,028
Closed -$245K 286
2022
Q3
$245K Sell
3,028
-188
-6% -$16.9K 0.01% 228
2022
Q2
$289K Buy
3,216
+1,136
+55% +$115K 0.01% 217
2022
Q1
$231K Buy
+2,080
New +$220K 0.01% 254
2018
Q4
Sell
-2,029
Closed -$200K 243
2018
Q3
$200K Buy
+2,029
New +$188K 0.02% 231
2018
Q2
Sell
-3,429
Closed -$275K 256
2018
Q1
$275K Buy
+3,429
New +$283K 0.02% 200

Other funds holding MDT

Aspiriant LLC's MDT Position: Q2 2026 in Review

Aspiriant LLC increased its Medtronic (MDT) stake by 3.8% in Q2 2026, buying an estimated $17K and bringing the position to 5,770 shares worth $451K. The position accounts for 0.01% of the portfolio, ranked #261.

Aspiriant LLC first reported a position in MDT in Q1 2018 and has held it in 16 quarters since. The position peaked at $482K in Q1 2026. 2,134 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

  • Aspiriant LLC held 5,770 shares of Medtronic worth $451K as of Q2 2026.
  • Aspiriant LLC bought 211 Medtronic shares in Q2 2026, an estimated $17K.
  • Medtronic made up 0.01% of Aspiriant LLC's portfolio in Q2 2026, its #261 holding.
  • Aspiriant LLC first reported a position in Medtronic in Q1 2018 and has held it in 16 quarters since.
  • Aspiriant LLC's Medtronic position peaked at $482K in Q1 2026.
  • 2,134 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on Aspiriant LLC's 13F filing for Q2 2026, filed 20 Jul 2026.